Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

A Peek Into The Markets: U.S. Stock Futures Drop Ahead Of Factory-Orders Report

Benzinga.com  July 5, 2016

Bristol-Myers Squibb Buys Privately Held Cormorant Pharmaceuticals

Benzinga.com  July 5, 2016

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Business Wire July 5, 2016

Annual Report 31.12.2015

UK Regulatory news services, from the LSE July 4, 2016

Notification of Significant Shareholding

UK Regulatory news services, from the LSE July 4, 2016

MSM - Lifting of Suspension Notice

UK Regulatory news services, from the LSE July 4, 2016

Subsidiary completes a transaction

UK Regulatory news services, from the LSE July 4, 2016

Holding(s) in Company

UK Regulatory news services, from the LSE July 4, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Business Wire June 30, 2016

BetterInvesting Magazine Releases September Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use

PR Newswire June 28, 2016

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer

Business Wire June 27, 2016

Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola

Business Wire June 24, 2016

Annual Financial Report

UK Regulatory news services, from the LSE June 24, 2016

Form 8.3 - Ball Corporation

UK Regulatory news services, from the BW June 24, 2016

Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer

Business Wire June 20, 2016

5 Pharmaceutical Price Target Raises from Jefferies

Benzinga.com  June 14, 2016

Technical Recap on Drug Manufacturers - Major Equities - Bristol-Myers Squibb, Eli Lilly, AstraZeneca, and GlaxoSmithKline

PR Newswire June 14, 2016

SunTrust Highlights Upcoming Pharma Calendar, Favorite Names

Benzinga.com  June 13, 2016

Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Benzinga.com  June 13, 2016

New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial

Business Wire June 10, 2016